How long should i wait between cosentyx and mmr shots?

Recommended Spacing Between Cosentyx and MMR Vaccine

Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis and other conditions, suppresses the immune system, reducing vaccine effectiveness and raising infection risk from live vaccines like MMR (measles, mumps, rubella).[1] Guidelines advise avoiding live vaccines during Cosentyx treatment and for varying periods after stopping.

Current Infectious Diseases Society of America (IDSA) and CDC recommendations: Do not give live vaccines to patients on immunosuppressive biologics like Cosentyx. After discontinuing Cosentyx, wait at least 3-6 months before live vaccines such as MMR to allow immune recovery, as secukinumab's half-life is about 27 days and full clearance takes 4-6 months.[1][2]

Timing If Starting Cosentyx After MMR

Reverse scenario is safer. MMR can be given any time before starting Cosentyx, ideally 4 weeks prior, since vaccine-induced immunity persists despite later immunosuppression. No minimum wait required post-vaccination before Cosentyx, but confirm immunity with titers if high-risk.[2][3]

Why the Wait for Live Vaccines?

Live vaccines replicate in the body to build immunity, but Cosentyx impairs this response and risks uncontrolled replication (e.g., measles dissemination). Inactivated vaccines (like flu shots) have no such spacing rules and can be given anytime during treatment.[1][3]

Exceptions and Special Cases

• Pregnancy or travel: Shorten to 3 months post-Cosentyx if urgent, per clinician judgment, but data is limited.[2]
  
• Children or immunocompromised: Pediatric dosing may extend clearance; consult pediatric infectious disease specialist.
  
• Prior immunity: If MMR titers show protection, vaccination may be skipped entirely.[3]
  
  Always check with your doctor or pharmacist for personalized advice based on dose, duration of Cosentyx use, and health status—guidelines evolve with new studies.
  
  Sources
  [1] CDC: General Best Practice Guidelines for Immunization - Special Situations
  [2] IDSA: 2013 Clinical Practice Guidelines for Vaccination of the Immunocompromised Host
  [3] Novartis Cosentyx Prescribing Information